Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methdilazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.84 |
| ▸ | DRD1 | P21728 | 3/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.84 |
| ▸ | DRD3 | P35462 | 3/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.84 |
| ▸ | HTR2A | P28223 | 2/20 | 0.84 |
| ▸ | HTR2B | P41595 | 2/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.84 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methdilazine SCHEMBL1518885 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL29415150 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL30903921 | 0.98 | CYP2D6 (0.97) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL28086451 | 0.98 | CYP2D6 (0.97) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL211226 | 0.98 | CYP2D6 (0.97) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Methdilazine SCHEMBL721595 | 0.97 | CYP2D6 (0.94) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| SCHEMBL14675038 | 0.92 | CYP2D6 (0.86) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Mepazine SCHEMBL17746928 | 0.91 | CHRM2 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Mepazine SCHEMBL29436812 | 0.91 | CHRM2 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 | |
| Mepazine SCHEMBL31281799 | 0.91 | CHRM2 (1.00) | CYP2D6CYP1A2CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6256 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025082959-A1 | A PHENOTHIAZINE-RELATED COMPOUND CONJUGATED TO A PEPTIDE | UNIVERSITY OF ULSTER (GB) | 2025-04-24 | — | — | WO | claimed |
| US-20230181556-A1 | USE OF PSYCHOTROPIC DRUGS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) | 2023-06-15 | — | — | US | claimed |
| EP-4178534-A1 | OPHTHALMIC FORMULATION AND METHODS OF USE | Alqallawi, Abdelhamid Muhammad (EG) | 2023-05-17 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4153158-A1 | USE OF PSYCHOTROPIC DRUGS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-03-29 | — | — | EP | claimed |
| US-20220280442-A1 | BIO-INSPIRED TISSUE-ADHESIVE HYDROGEL PATCH AND USES THEREOF | Cellartgen Inc. (KR) | 2022-09-08 | — | — | US | claimed |
| US-20220257780-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | BRILLIAN PHARMA INC. (US) | 2022-08-18 | — | — | US | claimed |
| EP-4041309-A1 | MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF | Brillian Pharma Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-1063221-A | POLYAMINE DRUG-RESIN COMPLEXES | RICHARDSON VICKS INC (US) | 1992-08-05 | — | — | CN | claimed |
| WO-1992011038-A1 | POLYAMINE DRUG-RESIN COMPLEXES | RICHARDSON-VICKS INC. (US) | 1992-07-09 | — | — | WO | claimed |
| CN-1057823-A | CINDER-FIBRE LIGHT CONCRETE | HUATONG NEW TECHNOLOGY INST CH (CN) | 1992-01-15 | — | — | CN | claimed |
| US-4996047-A | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |
| US-4749700-A | NASAL ADMINISTRATION LOWER DOSAGE | NASTECH PHARMACEUTICAL CO, INC. (US) | 1988-06-07 | — | — | US | claimed |
| US-4407800-A | TRYPANOCIDES | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1983-10-04 | — | — | US | claimed |
| US-4269835-A | Nasal composition for relieving nasal distress | WHITTLE BARRY J | 1981-05-26 | — | — | US | claimed |
| US-4104382-A | (((THIAZOLYL-, ISOTHIAZOLYL- OR PYRIDYLALKYL)THIO)ALKYL)GUANIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | claimed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | claimed |